CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

NICE recommends two treatments for DMO

The National Institute for Health and Care Excellence has recommended aflibercept and a dexamethasone implant for diabetic macular oedema

Guidelines issued for NHS logo use

The National Institute for Health and Care Excellence (NICE) has recommended two treatment options for diabetic macular oedema (DMO), publishing two separate pieces of guidance today (22 July).

The final guidance from the regulatory agency has approved the use of the anti-VEGF treatment aflibercept, marketed as Eylea by Bayer Pharma, for patients with a central retinal thickness of 400µm or more at the start of treatment. A restriction of the recommendation is the provision of the drug discounted under an agreed patient access scheme.

The second recommendation is for a dexamethsone intravitreal implant. The final guidance states that the treatment is only suitable for DMO patients with an intraocular lens who are non responsive to non-corticosteroid treatment, or such treatment is unsuitable.

Professor Carole Longson, director of the Health Technology Evaluation Centre at NICE, said: “Whilst these recommendations are for people with diabetic macular oedema needing different treatments at different stages of the disease, these decisions will be welcome news to both patients and healthcare professionals alike.”